GET DAILY SIGNALSRegeneron Pharmaceuticals (REGN) Stock Declines -15% Over 30 Days on Clinical Trial Setbacks
Key Takeaways
- REGN stock declined approximately 15% over the past 30 days amid disappointing clinical trial results for an experimental cancer drug and subsequent analyst downgrades.
- Over the past quarter, the stock fell about 19%, reflecting broader pressures from mixed first-quarter 2026 earnings and sector sentiment.
- Key drivers included a sharp sell-off following trial data releases and negative revisions to price targets.
- Positive developments, such as a $2.32 billion collaboration with Parabilis, provided limited offset to the negative momentum.
- Macroeconomic factors and biotech sector rotation contributed to sustained weakness.
- Investors should monitor upcoming pipeline updates and regulatory feedback for potential stabilization.
Regeneron Pharmaceuticals (REGN): Company Snapshot
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering, developing, and commercializing medicines for serious conditions in areas like eye health, inflammatory diseases, and oncology. Its approach relies heavily on proprietary antibody technologies and key partnerships, including the long-standing collaboration with Sanofi on products such as Dupixent. Operating in the competitive biopharmaceutical space, the company has built a solid base around established treatments like Eylea, yet recent pipeline challenges underscore the inherent risks that can quickly influence share prices.
REGN Stock Performance: Last 30 Days Compared to the Quarter
Over the last 30 days, REGN shares declined approximately 15%, moving from levels near $747 to a closing price of $638.88 on May 22, 2026. The path was largely trend-driven, with clear volatility tied to clinical news. Over the past quarter, the stock fell about 19%, dropping from around $771 to the recent close. This occurred along a fairly steady downward path, interrupted by earnings-related moves and wider sector pressures, keeping the shares range-bound inside an overall downtrend.
What Moved REGN in the Last 30 Days
The main catalyst was disappointing results from an experimental cancer drug trial. That news sparked an immediate 10.5% single-day drop and led to several analyst downgrades along with lower price targets. This company-specific event overshadowed a positive $2.32 billion collaboration announcement with Parabilis aimed at therapies for difficult-to-drug proteins. Investor focus shifted toward pipeline risks, while broader biotech sector rotation added to the downward pressure. No major macroeconomic changes directly hit the stock, but the trial outcome dominated trading and sustained selling pressure.
Quarterly Performance Influences on REGN
The wider quarterly decline reflected the combined impact of first-quarter 2026 earnings, which showed revenue growth of 19% to $3.6 billion but a 10% drop in GAAP net income. Industry developments in oncology and competitive positioning within biotech added caution. Macroeconomic factors, including interest-rate sensitivity for growth-oriented biotechs, weighed on valuations. Institutional selling and negative investor reaction after the clinical data release had the strongest cumulative effect, outweighing the positive collaboration news.
REGN Stock Forecast Drivers: What Comes Next
Investors should monitor upcoming clinical trial readouts, especially in oncology, along with any regulatory feedback on pipeline candidates. Industry trends in antibody-based therapies and potential new partnerships remain relevant. The broader macroeconomic environment, including interest rates and biotech funding conditions, could influence sentiment. Strategic items such as earnings guidance updates or competitive product launches also warrant attention, as do any shifts in analyst coverage.
Exploring AI Trading Bots for Portfolio Insights
When reviewing stocks like REGN, I sometimes look at Tickeron’s Trending AI Robots page to see how top-performing automated strategies are behaving across the market. It highlights a curated selection of the highest-ranked AI trading bots from the platform’s library, based on performance metrics, with transparent historical results and ongoing signals. Bots vary by strategy, timeframe, and risk parameters, which can help match different investor approaches. The page offers a straightforward way to review current options without needing to sift through hundreds of alternatives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
REGN in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 56 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 31 of 50 cases over the following month. The odds of a continued upward trend are 62%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +17.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 202 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 186 of 268 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.121) is normal, around the industry mean (3.104). P/E Ratio (22.958) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (129.907) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement